Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Beauty Health (SKIN) EBITDA Margin (2020 - 2026)

SkinHealth Systems has reported EBITDA Margin over the past 6 years, most recently at 9.42% for Q4 2025.

  • Quarterly EBITDA Margin rose 683.0% to 9.42% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.33% through Dec 2025, up 855.0% year-over-year, with the annual reading at 1.33% for FY2025, 855.0% up from the prior year.
  • EBITDA Margin was 9.42% for Q4 2025 at SkinHealth Systems, up from 15.02% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 41.52% in Q1 2022 and troughed at 317.96% in Q3 2021.
  • The 5-year median for EBITDA Margin is 8.5% (2025), against an average of 33.15%.
  • Year-over-year, EBITDA Margin plummeted -31187bps in 2021 and then surged 31603bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 26.51% in 2021, then skyrocketed by 134bps to 8.89% in 2022, then crashed by -185bps to 7.58% in 2023, then crashed by -114bps to 16.25% in 2024, then soared by 42bps to 9.42% in 2025.
  • Per Business Quant, the three most recent readings for SKIN's EBITDA Margin are 9.42% (Q4 2025), 15.02% (Q3 2025), and 29.85% (Q2 2025).